Background Despite widespread antiretroviral coverage in Botswana, Kaposi's sarcoma
Background
Kaposi's sarcoma (KS) is a vascular malignancy caused by human herpes virus 8 (HHV8) infection that predominantly affects the skin, lymphatics, and gastrointestinal tract in immunocompromised hosts. 1, 2 While antiretroviral therapy (ART) has a substantial impact on KS incidence in resource-rich settings, KS continues to cause significant morbidity and mortality in sub-Saharan Africa (SSA), ranking among the most commonly reported malignancies in this region despite similarly widespread availability of ART. 3, 4 This disparity has been attributed to the scale of the human immunodeficiency virus (HIV) epidemic, delayed access to ART, and higher sero-prevalence of HHV8 in SSA. 5, 6 While management for limited stage disease primarily involves optimizing management of HIV with ART, chemotherapy or radiation are required when disease is more extensive or refractory. [7] [8] [9] [10] [11] These additional therapies carry the potential for serious adverse effects, emphasizing the importance of correct diagnosis and the need for ongoing characterization of the affected population.
The demographics, clinical presentations, and outcomes of adult KS in Botswana are not well characterized. A recent prospective cohort study of 207 patients with KS receiving oncologic treatment in Botswana reported male gender and low CD4 cell count as risk factors. 12 In this cohort, 45% of patients were receiving ART prior to their diagnosis of KS, and a majority of the remaining patients were ART-eligible (CD4 <250 cells/ll). 12, 13 It was proposed that late initiation of ART, particularly in men, and low recognition of early stage KS remained barriers to decreasing disease incidence and progression. Better characterization of the risk factors for KS may allow for earlier and more accurate clinical suspicion of the disease.
In resource-rich settings, the diagnosis of KS is routinely confirmed with histopathology; however, diagnosis in resource-limited settings is challenging due to lack of access to dermatologists, supplies, and the scarce availability of dermatopathology services. In a survey study of SSA nations, 86% of countries reported having histology processing services and a pathologist, but only 14% reported having a dermatopathologist. 14 
Results

Dermatology cohort
A total of 441 patients had biopsies performed for clinical suspicion of KS in the dermatology clinic at PMH during the study period ( Table 1 A total of 239 (54%) patients were ultimately diagnosed with KS on histopathology, while alternate diagnoses were made in 188 (43%) patients. A final diagnosis was not available for the remaining 14 (3%) patients either due to insufficient biopsy specimens or unavailable pathology reports.
Characteristics of cases confirmed to be KS While the age was similar for those diagnosed with KS compared with those with alternative diagnoses (Table 1) 
PPV of clinical suspicion of KS
A total of 450 biopsies were obtained from 441 patients, and a definitive diagnosis was made for 414 specimens. Two hundred and thirty-nine biopsies were ultimately interpreted as KS, which corresponds to a PPV of 58% when there was any mention of KS on the clinical differential diagnosis. Nine patients were e N = 11 not reported/processed plus N = 3 insufficient specimens and no repeat pathology performed.
biopsied twice, and two were found to have KS on repeat biopsy when the initial biopsies were indeterminate. When KS was not found, a variety of other diagnoses were made (Table 2) . Overall, 84% of alternate diagnoses were medically significant in that they merited management that differs from that of KS with 5% of these being acute or life-threatening conditions. The remaining 16% of alternate diagnoses were clinically benign conditions. for ART, regardless of CD4 cell count. 13 Data on the specific ART regimens were available for 45 patients, and the most commonly received first-line therapy consisted of tenofovir and emtricitabine in combination with either nevirapine or efavirenz.
Treatment modalities
For those referred to oncology (n = 40), most received additional therapy. Thirty-one patients received chemotherapy (78%), and three of these patients also received radiation (8%).
Most patients received low-dose bleomycin, doxorubicin, and vincristine (ABV) every 3 weeks, and one patient received paclitaxel.
Discussion
KS continues to cause a significant disease burden in Botswana despite improved ART coverage in the region. This apparent heterogeneity of KS remains insufficiently understood as does the accuracy of current diagnostic practices for this malignancy.
In this study, a majority of patients diagnosed with KS were male, HIV positive, and had significantly lower CD4 cell counts than those with alternative diagnoses on histopathology, which are consistent with prior studies from countries throughout SSA. 12, [18] [19] [20] [21] [22] The average age of our KS cohort was also similar to those reported in the literature (mid to late 30s). 12, 19, 20 Endemic KS, KS occurring in absence of HIV infection, accounted for only a limited proportion of cases (6.4%).
Overall, there was a relatively low (58%) PPV for clinical suspicion of KS with a significant number of patients whose histopathology ultimately revealed other significant or life-threating conditions requiring alternative therapies (84%). Our data suggest that clinical suspicion alone is not always a reliable means for diagnosis given the implications of mistreatment. Our findings were similar to other PPVs reported in recent studies from other countries in SSA, ranging from 57% to 77%. [15] [16] [17] KS is a condition with multiple morphologic variants, and the numerous conditions that can mimic KS clinically contribute to the overall poor PPVs for clinical suspicion of the disease. This underscores the important role of histopathology in definitively diagnosing KS. (2) Aspergillosis (1) Warts (2) Epidermodysplasia verruciformis (1) Folliculitis (1) Cellulitis (1) Molluscum ( Given the overall poor PPV of clinical diagnosis of KS, improving accessibility to biopsy would likely improve diagnostic accuracy and treatment, but this can present logistical challenges in resource-limited settings. Pathology is costly and not only are the staff, clinic space, and materials for performing biopsies limited, but the availability of pathologists and the accuracy of histopathologic diagnosis may limit the utility. The quality of tissue processing may be affected and, in many of these settings, histopathologic diagnosis relies on pathologists without expertise in dermatopathology and without access to diagnostic adjuncts such as immunohistochemical stains. 16 Without specific training in dermatopathology, diagnostic accuracy may be lower and result in missed diagnoses of KS. In a prior study, the concordance of African and U.S.-based pathologists for the diagnosis of KS was only 69%. 15 In addition, sent out specimens are commonly lost and results are often considerably delayed.
Our study has several limitations. This is a retrospective review and relies upon data previously entered, which may be incomplete. Data were only available for patients ultimately biopsied for suspected KS, so patients with more classic disease may not be represented, falsely lowering the PPV. Fewer than expected KS positive patients overlapped with the BPCC database. Future studies should aim to follow this population prospectively, monitoring responses to treatment and mortality to further characterize KS patients in Botswana with respect to severity and outcomes.
Our study reinforces the risk factors in development of KS including HIV positivity, male gender, and lower CD4 cell counts. We also found that clinical suspicion of KS alone is not sufficient for diagnosis, and histopathology is imperative for definitive diagnosis to ensure that proper treatment is initiated and to help prevent unnecessary, potentially dangerous overtreatment with chemotherapy or radiation when not indicated. We recognize that there are instances where waiting for histopathologic diagnosis could potentially delay treatment to acutely ill patients. While we emphasize the importance of histopathologic diagnosis, there may be situations where empiric treatment can be life-saving, particularly given the delays in histopathology experienced in low-resource settings.
In these situations, clinicians should aim to balance resource utilization with clinical acumen when taking care of patients.
Emerging point-of-care and rapid diagnostic tests for KS, should they prove to be sufficient for diagnosis, may have the potential to improve access to accurate diagnosis by overcoming the time and resource burden of histopathology.
